CN111905101A - Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug - Google Patents
Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug Download PDFInfo
- Publication number
- CN111905101A CN111905101A CN202010636864.8A CN202010636864A CN111905101A CN 111905101 A CN111905101 A CN 111905101A CN 202010636864 A CN202010636864 A CN 202010636864A CN 111905101 A CN111905101 A CN 111905101A
- Authority
- CN
- China
- Prior art keywords
- tumor
- antibody
- cytokine
- drug
- cytokine drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 184
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 145
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title claims abstract description 117
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title claims abstract description 116
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 229940079593 drug Drugs 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 36
- 239000002086 nanomaterial Substances 0.000 claims abstract description 29
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 18
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 15
- 238000002512 chemotherapy Methods 0.000 claims abstract description 6
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 5
- 239000011886 peripheral blood Substances 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 27
- 208000029742 colonic neoplasm Diseases 0.000 claims description 27
- 206010057249 Phagocytosis Diseases 0.000 claims description 16
- 230000008782 phagocytosis Effects 0.000 claims description 16
- 238000009169 immunotherapy Methods 0.000 claims description 13
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 10
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 210000001539 phagocyte Anatomy 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000002626 targeted therapy Methods 0.000 claims description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 238000001815 biotherapy Methods 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 238000002647 laser therapy Methods 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 238000000015 thermotherapy Methods 0.000 claims description 2
- 230000005748 tumor development Effects 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 163
- 210000002540 macrophage Anatomy 0.000 abstract description 40
- 210000000987 immune system Anatomy 0.000 abstract description 11
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 10
- 206010067484 Adverse reaction Diseases 0.000 abstract description 6
- 230000006838 adverse reaction Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 6
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 101150036449 SIRPA gene Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000032832 immune response to tumor cell Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An application of the CD47 antibody and IL-6 cytokine in treating tumor and its method for treating tumor are disclosed, which features that the forward action of IL-6 on immune system is used to cooperate with the CD47 antibody to treat tumor, so activating macrophage to kill tumor cells and improving immunity. Can further realize the immune response of tumor cells based on IL-6 activated T cells and the like, improve the response rate of combined application for treating tumors, fully activate the anti-tumor effect of the immune system of an organism, and can obviously reduce adverse reactions compared with other methods such as chemotherapy and the like. The invention also can improve the treatment targeting property by loading the IL-6 cytokine drug on the nano material with the targeted tumor or tumor microenvironment, enrich the IL-6 in the tumor microenvironment, reduce the amount of the IL-6 entering peripheral blood, reduce side effects, more fully exert the amount of the CD47 antibody reaching the tumor, reduce the dosage of the single action thereof and realize complete combined application.
Description
Technical Field
The invention relates to the field of medical treatment, in particular to application of a CD47 antibody and an IL-6 cytokine drug in tumor treatment and a method for verifying tumor treatment by the same.
Background
CD47 is also called integrin-associated protein, and its ligand is the signal regulatory protein alpha chain (SIRP alpha) on the surface of macrophage, and when CD47 binds with SIRP alpha, it can transmit inhibition signal to inhibit phagocytic activity of macrophage. The tumor cells express CD47 and combine with macrophage SIRP alpha to promote the immune escape of the tumor cells, so that the phagocytosis of the huge macrophages cannot be fully exerted, and the influence of the macrophages on the development of the tumor is reduced. On the basis, aiming at achieving the purpose of treating tumors, the prior art researches have medicines for blocking a CD 47-SIRPa pathway and targeting CD47, including CD47 antibodies, but most indications of the medicines are concentrated on malignant blood tumors, few are directed to solid tumors, and the medicines are basically in the clinical stage I. In addition, clinical experiments show that the blood toxicity provides challenges for the drug development design and clinical dose tolerance of the target drug, and the selection of an animal model also has a small challenge for evaluating the effectiveness and safety of the drug; therefore, the development of CD 47-targeted antibody drugs is still further advanced.
IL-6 is a multifunctional cytokine produced by macrophages, fibroblasts and T cells, and has the functions of activating T cells, preventing apoptosis, inducing macrophage activation, recruiting immune cells and the like to regulate immune response. Current studies have shown that it promotes tumor cell survival and also contributes to immunosuppression of CD4+T cell mediated antitumor effect, and high level of IL-6 and tumor patients with poor prognosis associated with. However, Elisabeth et al have recently found that blocking the TNF pathway significantly enhances the effect of immunotherapy, while blocking the IL-6 pathway significantly inhibits the effect of immunotherapy, after administering anti-CTLA-4 and anti-PD-1 to a mouse tumor model. It is suggested that IL-6 is not the only inhibitor of the immunotherapeutic process.
If tumors could be treated by increasing the appropriate concentration of IL-6 in conjunction with the CD47 antibody, it may be possible to significantly increase the efficacy of the treatment of tumors over the prior art using the CD47 antibody alone.
At present, the report of the combination of IL-6 cytokine and CD47 antibody for resisting tumor is not available.
Disclosure of Invention
The invention aims to overcome at least one defect of the prior art, and provides an application of a CD47 antibody and an IL-6 cytokine drug in tumor treatment and a verification method for treating tumors thereof, wherein the IL-6 cytokine with a proper concentration or the drug for promoting cells to generate the IL-6 cytokine is combined with anti-CD-47 to treat the tumors, so that the ability of macrophages to phagocytose tumor cells can be effectively enhanced, the tumor immunotherapy effect is improved, the life cycle of tumor patients is prolonged, and a new choice is provided for clinical immunotherapy; the method for treating the tumor in a combined manner can further confirm that the CD47 antibody and the IL-6 cytokine drug can effectively improve the immunotherapy effect, so as to provide a new tumor treatment direction based on the effect.
The technical scheme adopted by the invention is as follows:
the invention provides an application of a CD47 antibody and an IL-6 cytokine drug in preparation of antitumor drugs, wherein the IL-6 cytokine drug comprises an IL-6 cytokine and/or an IL-6 cytokine promoting drug, and the basis is the combined use of a CD47 antibody and the IL-6 cytokine. The positive effect of IL-6 on an immune system is utilized to cooperate with the CD47 antibody to treat the tumor, for example, the IL-6 is utilized to promote the polarization effect of cytoskeleton in the phagocytosis process of macrophages to cooperate with the CD47 antibody to treat the tumor, thereby being beneficial to fully activating the macrophages to kill tumor cells and improving the immunotherapy effect taking the CD47 antibody as the leading antibody. And immune cells such as T cells activated based on IL-6 can further promote the immune response to tumor cells, improve the response rate of combined application for treating tumors, fully activate the anti-tumor effect of the immune system of an organism, and obviously reduce adverse reactions compared with other methods such as chemotherapy and the like. The improvement of the tumor treatment effect of the CD47 antibody and the IL-6 cytokine can prolong the survival time of tumor patients and improve the survival rate of the tumor patients. And treatment based on the body's own immune system also helps to reduce the possibility of recurrence and metastasis. The IL-6 cytokine is used in combination with the CD47 antibody at a specific concentration, and IL-6 is used in combination with the CD47 antibody at a higher and moderate concentration, since an excessively high concentration may cause an adverse reaction of the immune system to itself. The invention can directly use IL-6 cytokine and CD47 antibody to be used together, can use IL-6 cytokine medicine and CD47 antibody to be used together, and can also use IL-6 cytokine, IL-6 cytokine medicine and CD47 antibody to be used together. Because the IL-6 cytokine-promoting drug can promote the production of IL-6 cytokine by cells including phagocytes, it can play at least the same role as IL-6 cytokine, and based on the IL-6 cytokine-promoting drug also helps to utilize its effects other than the production of IL-6 cytokine in cooperation with IL-6 for further antitumor.
Further, the IL-6 cytokine-promoting drugs comprise BayK8644 reagent and/or Etoposide (VP-16) and the like, and the BayK8644 can induce the IL-6 expression of macrophages, so that the enrichment of IL-6 cytokines is facilitated. Etoposide (VP-16) is a common anti-tumor chemotherapeutic agent, can promote IL-6 cytokine production, and can also cooperate with CD47 antibody and IL-6 produced to resist tumor together by using the characteristics of Etoposide, thereby obviously improving the anti-tumor effect.
Further, the IL-6 cytokine drug is loaded on the nano material targeting the tumor or the tumor microenvironment. Compared with a single tumor cell, the absorption capacity of the single macrophage for the nano material is thousands of times of the absorption capacity of the single macrophage, namely the macrophage can be used as a 'reservoir' of the nano material to enrich the nano material in a tumor microenvironment. The appropriate amount of the IL-6 cytokine drug is modified on the nano material, so that the IL-6 cytokine drug is enriched in a tumor microenvironment, particularly macrophages in the tumor microenvironment, and the high concentration of the IL-6 cytokine drug and the CD47 antibody act on tumor tissues together, the capability of the macrophages in phagocytosing tumor cells is enhanced, and the immune response of an immune system to the tumor cells is promoted. Thereby effectively treating the tumor, prolonging the life cycle of a patient and providing a new choice for the treatment of the clinical tumor (such as colon cancer) at present. In addition, the nano material can freely pass through gaps of tissues and capillaries in a human body, and even can pass through a blood brain barrier, so that the targeted transportation of an IL-6 cytokine-carrying drug to a tumor or a tumor microenvironment is facilitated, the targeted therapy is realized, and the therapeutic effect is further improved; and the targeted delivery of IL-6 cytokine drugs also helps to reduce the IL-6 concentration in the peripheral blood, thereby reducing the side effects caused by high concentrations of IL-6.
Further, the anti-tumor drug is administered in combination with at least one anti-cancer treatment selected from the group consisting of immunotherapy, chemotherapy, radiotherapy, angiogenesis inhibitor therapy, biologic therapy, bone marrow transplantation, peripheral blood stem cell transplantation, thermotherapy, laser therapy, photodynamic therapy, cancer-targeted therapy. In addition to the combination of an IL-6 cytokine drug and an antibody to CD47 to achieve and enhance immunotherapeutic effects, the combination can be used in combination with other therapies or drugs to further enhance the therapeutic effects of tumors.
Furthermore, in the using process of the anti-tumor drug, the IL-6 cytokine drug is enriched in a tumor microenvironment, and then the CD47 antibody acts on the tumor. The enrichment of IL-6 in a tumor microenvironment can be realized before the CD47 antibody reaches tumor tissues, the concentration of the antibody which acts with the CD47 antibody is improved in a tumor microenvironment in an enrichment mode, the CD47 antibody is used as a main factor to act on tumors quickly in a combined mode, and partial dosage of the CD47 antibody is prevented from acting on the tumors when the IL-6 concentration does not reach adaptive concentration, so that the treatment effect of combining IL-6 cytokines and the CD47 antibody is further improved. Compared with the simultaneous administration with the CD47 antibody, the method relaxes the requirement on the concentration of the IL-6 cytokine drug during administration, and is beneficial to simplifying dosage and operation and achieving the same technical effect.
Further, the tumor is a hematological tumor or a solid tumor. Because of the specificity of IL-6 cytokines, particularly as an inflammatory cytokine, which recruits immune cells, at least tumor-targeted immune cells, including solid tumors, can be recruited by tumor-targeted IL-6 to achieve anti-tumor. And both the CD47 antibody and the IL-6 cytokine can activate macrophages, so that the combination of the CD47 antibody and the IL-6 cytokine can obviously improve the immune function of the macrophages when being applied to solid tumors, thereby realizing the effective treatment of the solid tumors. Meanwhile, the CD47 antibody is an effective blood tumor treatment substance, and the combination of the CD47 antibody and IL-6 cytokines can also realize improvement of the treatment effect on blood tumors.
Further, the tumor is colon cancer. Colon cancer is the most common malignancy of the digestive tract, with the third in global tumor incidence and the second in mortality. At present, the incidence rate of the Chinese medicine is always in an increasing trend in China. In the prior art, the treatment means for colon cancer mainly comprises three traditional treatment methods of operation, radiotherapy and chemotherapy, but the recurrence and metastasis after treatment are still obvious, and the toxic and side effects are not negligible. The invention is characterized in that IL-6 cell factor with properly increased concentration is combined with CD47 antibody to be administered, IL-6 cell factor belongs to the material of immune system, and the combined administration of IL-6 cell factor and anti-CD47 antibody has improved immunotherapy effect compared with the administration of CD47 antibody alone, therefore, when the same therapy effect is achieved, the combined administration can reduce the dosage of CD47 antibody, thereby reducing the adverse reaction caused by CD47 antibody acting on normal cells. The treatment of colon cancer based on the IL-6 cytokine + CD47 antibody is helpful for providing a basis for the application of the subsequent research to clinical medicines and providing a direction for treating colon cancer.
A kit comprising a CD47 antibody and an IL-6 cytokine drug, said IL-6 cytokine drug comprising an IL-6 cytokine and/or a pro-IL-6 cytokine drug. The kit is applied to tumor treatment, and further applied to colon cancer treatment. The CD47 antibody and the IL-6 cytokine in the kit are prepared into pharmaceutically acceptable reagents by pharmaceutically acceptable pharmaceutical carriers. The kit can realize the combination of the CD47 antibody and the IL-6 cytokine drug, namely the combination of the CD47 antibody and the IL-6 cytokine, thereby improving the effect of activating macrophages based on the IL-6 and CD47 antibodies, promoting the activation of the macrophages and killing tumor cells, promoting the response of immune cells such as T cells and the like, and fully playing the anti-tumor effect of the immune system of an organism.
Further, the tumor cell material also comprises a nano material for loading IL-6 cytokine drugs to target tumors or tumor microenvironment. The nano material loaded with the IL-6 cytokine drug is beneficial to targeted transportation, so that the IL-6 cytokine is directly concentrated in a tumor microenvironment or indirectly concentrated in the tumor microenvironment through the IL-6 cytokine drug, on one hand, adverse reaction caused by concentration of the IL-6 in normal tissues can be avoided, on the other hand, the IL-6 can be concentrated in macrophages in the tumor microenvironment, and therefore, the concentration of the IL-6 is high, and the IL-6 can jointly act on tumors when the CD47 antibody arrives, so that an effective anti-tumor effect is realized.
Further, an IL-6 cytokine drug is loaded on the nanomaterial and administered prior to the CD47 antibody; alternatively, the IL-6 cytokine drug is loaded on a nanomaterial and administered concomitantly with the CD47 antibody. When the IL-6 cytokine drug is loaded on the nano material and is administered before the CD47 antibody, the targeted enrichment of IL-6 can be realized before the CD47 antibody reaches the tumor tissue, the concentration of the antibody which interacts with the CD47 antibody is increased by the enrichment in the tumor microenvironment, the CD47 antibody is used as the main factor to quickly combine and act on the tumor, and the partial dosage of the CD47 antibody can be prevented from acting on the tumor when the IL-6 concentration does not reach the adaptive concentration. In addition to loading the IL-6 cytokine drug on the nanomaterial prior to administration of the CD47 antibody, the IL-6 cytokine drug can be concomitantly administered with the CD47 antibody, but it is necessary to administer a specific high concentration of the IL-6 cytokine drug prior to administration so that it has or produces a concentration of IL-6 cytokine adapted to act in combination with the CD47 antibody when targeted to the tumor, in a manner that also achieves the effect of treating the tumor with the combination, but requires precise control of the amount compared to the manner in which the IL-6 cytokine drug is loaded on the nanomaterial and administered first.
It is another object of the present invention to provide a method for verifying that the CD47 antibody is used in combination with an IL-6 cytokine drug to effectively treat a tumor, comprising the steps of:
s1, in-vitro phagocytosis detection, namely detecting the influence of the IL-6 cytokine drug on the phagocytosis of the CD47 antibody on the phagocytosis of the phagocyte by comparing the influence of the independent CD47 antibody and the CD47 antibody in combination with the IL-6 cytokine drug on the process of the phagocyte for phagocyting tumor cells;
s2, animal tumor model-based tumor therapy testing, the effect of IL-6 cytokine drugs on the anti-tumor effect of CD47 was verified by comparing the effect of CD47 antibody alone and CD47 antibody in combination with IL-6 cytokine drugs on tumor development.
Compared with the prior art, the invention has the beneficial effects that: the positive effect of IL-6 on an immune system is utilized to cooperate with the CD47 antibody to treat the tumor, for example, the IL-6 is utilized to promote the polarization effect of cytoskeleton in the phagocytosis process of macrophages to cooperate with the CD47 antibody to treat the tumor, thereby being beneficial to fully activating the macrophages to kill tumor cells and improving the immunotherapy effect taking the CD47 antibody as the leading antibody. Can also further realize the immune response of tumor cells based on IL-6 activated T cells and the like, improve the response rate of combined application for treating tumors, and fully activate the anti-tumor effect of the immune system of the organism. Compared with other methods such as chemotherapy and the like, the method can obviously reduce adverse reactions based on immunotherapy, more importantly, the invention also loads IL-6 cytokine drugs through the nano material with the targeted tumor or tumor microenvironment, can improve the targeting of the therapy, can enrich IL-6 in the tumor microenvironment, can reduce the amount of IL-6 entering peripheral blood in the transportation process, reduce side effects, can fully exert the dosage of CD47 antibodies of the reached tumor based on the enriched IL-6, reduce the dosage of CD47 acting on the tumor alone and realize complete combined application. And the IL-6 cytokine drug can be fully absorbed and enriched by macrophages based on the nano material, and can directly act on the macrophages to improve the activity and the efficiency of the macrophages. Meanwhile, the IL-6 cytokine drug and the CD47 antibody are combined for immunotherapy to treat solid tumors including colon cancer, and the restriction that the CD47 antibody in the prior art is difficult to realize effective treatment effect on the solid tumors is broken through; provides a new research direction for immunotherapy and colon cancer therapy in the prior art and promotes the development of the field of tumor therapy.
Drawings
FIG. 1 is a schematic diagram of the addition of 24-well plate material in the in vitro phagocytosis assay of phagocytes according to the present invention.
Detailed Description
The invention is described in further detail below with reference to the drawings and specific examples, which are provided for illustration only and are not intended to limit the scope of the invention. The test methods used in the following examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
The following examples relate to practices and apparatus including: RAG-1KO mouse (offered by Zhan institute of medicine, Zhongshan university, Yonghan institute of Okinawa, Biotech, Inc.), C57BL/6 mouse (purchased from Jiangsu Jiejiaokang Biotech, Inc.), MC38 cell line (offered by Xurui institute of Ohwi, Inc., affiliated with Zhongshan university, Okinawa's research group), Anti-CD47 (purchased from Bioxcell, BE0270, clone No.: MIAP301), Anti-CSF-1R (purchased from Bioxcell, BE0213, clone No.: AFS98), Anti-CD8 α (purchased from Bioxcell, BE0061, clone No.: 2.43), nanomaterial, CFSE (C34554; Life Technologies, Burleore, Ontario, Canada), IL-6(216-16, PeproTech, Rocky Hicky, USA), cell culture medium (Hybc, serum (USA, USA), flow cytometry, USA, Biotech, USA, Fisher 2), and Nippo, USA 32).
Example 1
In vitro macrophage phagocytosis assay of CD47 antibody alone and CD47 antibody in combination with IL-6 cytokine drug or with IL-6 cytokine drug loaded on nanomaterials
S1, obtaining and culturing macrophages in vitro; in this example, bone marrow was removed from the leg bone of a mouse, and macrophages were cultured in vitro. And macrophages were plated onto 24-well plates overnight at 5X 10 per well4And macrophages are formed.
S2, and in-vitro macrophage phagocytosis colon cancer cell detection based on a CD47 antibody, a CD47 antibody and an IL-6 cytokine drug, and a CD47 antibody and the IL-6 cytokine drug loaded on a nanometer material.
In this example, the macrophage medium was replaced with serum-free medium at 37 ℃ with 5% CO2Incubating for 2h in an incubator;
then 2 is taken out5After washing each colon cancer cell line (MC38) in PBS solution, it was stained with CFSE, and then 10ug/mL lgG or CD47 antibody was added according to the treatment group, and PBS or 100ng/mL IL-6 or 100ng/mL nano-IL-6, which is nano material, was added, and the nano-IL-6 was IL-6 cytokine loaded on the nano material. The 100ng/mL IL-6 may be replaced with 5. mu.g/mL BayK8644 or Etoposide (VP-16) in a specified amount or other chemical capable of inducing IL-6 production in a specified amount, the BayK8644 or Etoposide (VP-16) or other chemical capable of inducing IL6 being capable of inducing IL-6 expression by macrophages, increasing IL-6 concentration in the tumor microenvironment.
Specifically, as shown in FIG. 1, the substances and the corresponding wells are combined with each other to obtain the phagocytic result of colon cancer cells phagocytized by phagocytes corresponding to lgG, lgG + PBS, lgG + IL-6, lgG + nano-IL-6, anti-CD47, anti-CD47+ PBS, anti-CD47+ IL-6, anti-CD47+ nano, anti-CD47+ nano-IL-6, which are not added with any substance, respectively, wherein the anti-CD47 is CD47 antibody. Thus, the anti-CD47+ nano-IL-6 has specificity compared with any other combination, and has the obvious effect of promoting macrophages to phagocytose colon cancer cells.
Specifically, in this example, after floating tumor cells were washed out with PBS in each well, 5 fields were arbitrarily photographed with a fluorescence microscope, and the phagocytosis rate was calculated. The phagocytosis rate is the number of tumor cells phagocytosed/(number of all macrophages in the field x 100), and was repeated three times per experiment.
The experimental results show that: the phagocytosis rate of the anti-CD47+ nano-IL-6 group is greater than that of the anti-CD47+ IL-6 group is greater than that of the other groups, the phagocytosis rate of the anti-CD47+ nano-IL-6 group is the highest, the anti-CD47 and the IL-6 can promote macrophages to phagocytose colon cancer cells, and especially when the IL-6 is loaded on a nano material for drug application, the effect is more obvious.
Example 2
Treatment of colon cancer in RAG-1KO mouse subcutaneous transplantation tumor model by using CD47 antibody alone and CD47 antibody in combination with IL-6 cytokine drug or in combination with IL-6 cytokine drug loaded on nano material
S1, the colon cancer cell line is transplanted to the right side of a RAG-1KO mouse subcutaneously, and a transplantation tumor model is constructed. In this example, 5X 105A colon cancer cell line (MC38) was implanted subcutaneously on the right side of RAG-1KO mice.
S2, comparing the effect of colon cancer treatment with CD47 antibody alone, CD47 antibody in combination with IL-6 cytokine drug based on the transplanted tumor model, wherein the CD47 antibody in combination with IL-6 cytokine drug comprises CD47 antibody in combination with IL-6 cytokine drug loaded on nano material. In this example, mice were divided into eight different treatment groups, each treatment group consisting of 5 mice, each treatment group consisting of lgG + PBS, anti-CD47+ PBS, lgG + IL-6, anti-CD47+ IL-6, lgG + nano, anti-CD47+ nano, lgG + nano-IL-6, and anti-CD47+ nano-IL-6. The IL-6 may be replaced with specific amounts of BayK8644 or Etoposide (VP-16) or other chemical capable of inducing IL-6, the nano-IL-6 may be replaced with specific amounts of nano-BayK8644 or nano-Etoposide (VP-16) or nano-other chemical capable of inducing IL6, and other embodiments are equally capable of IL-6 or nano-IL-6 replacement based thereon.
Injection of drugsAfter 7 days, when the tumor volume grows to 50-100mm3When the injection is carried out, the corresponding groups are respectively matched and injected with 200ug anti-CD47, 200ug lgG, 500ng or 1ug IL-6 (or 150ug or 200ug BayK8644 intraperitoneally or specific amount of Etoposide (VP-16) or other chemical drugs capable of inducing IL-6), 500ng or 1ug nano-IL-6 intravenously or 150ug or 200ug nano-BayK8644 or specific amount of nano-Etoposide (VP-16) or nano-other chemical drugs capable of inducing IL-6) and PBS, and the injection is carried out once every three days for 4 times. And mice tumors were examined every three days for length (L), width (W) and height (H), and tumor volume was calculated as L W H/2. When the tumor volume of the mice in any one of the four groups of mice exceeds 1000mm3Mice from all treatment groups were sacrificed immediately and finally analyzed for tumor volume growth trends and tumor microenvironment.
The results show that: the anti-CD47+ nano-IL-6 group tumor size is smaller than that of the anti-CD47+ IL-6 group tumor size is smaller than that of other group tumors, animal experiments prove that the anti-CD47 and the IL-6 can effectively treat tumors, and the treatment effect is more obvious by loading the IL-6 on the nano material.
S3, comparing the effect of colon cancer treatment with CD47 antibody alone, CD47 antibody in combination with IL-6 cytokine drug, CD47 antibody in combination with IL-6 cytokine drug and CSF-1R based on the transplanted tumor model.
Take 5X 105A colon cancer cell line (MC38) was implanted subcutaneously on the right side of RAG-1KO mice. Mice were divided into three different treatment groups, 5 mice each: three groups are injected with lgG + PBS, anti-CD47+ nano-IL-6, anti-CD47+ nano-IL-6+ CSF-1R antibody respectively. After 7 days, when the tumor volume grows to 50-100mm3When in use, the corresponding matched injections of the corresponding groups are performed based on lgG, PBS, anti-CD47, nano-IL-6 and CSF-1R anti body, and the injections are performed once every three days for four times in total. Mice were examined every three days for length (L), width (W) and height (H) of tumors, tumor volume was calculated as L W H/2, and tumor volume growth trends and tumor microenvironment were analyzed. Likewise, the IL-6 may be replaced with specific amounts of BayK8644 or Etoposide (VP-16) or other chemical agent capable of inducing IL-6, and the nano-IL-6 may beCertain amounts of nano-BayK8644 or nano-Etoposide (VP-16) or nano-other chemical capable of inducing IL6 were used instead.
The results show that: the anti-CD47+ nano-IL-6 group tumor size is less than anti-CD47+ nano-IL-6+ CSF-1Rantibody group tumor size is less than lgG + PBS group tumor size, which indicates that the anti-tumor effect of nano-IL-6 on promoting anti-CD47 is mediated by macrophages.
Example 3
Treatment of colon cancer in C57BL/6 mouse subcutaneous transplantation tumor model by using CD47 antibody alone and CD47 antibody in combination with IL-6 cytokine drug or in combination with IL-6 cytokine drug loaded on nanometer material
S1, the colon cancer cell line is transplanted to the right side of the C57BL/6 mouse subcutaneously, and a transplantation tumor model is constructed. In this example, 1X 106A colon cancer cell line (MC38) was implanted subcutaneously into the right side of C57BL/6 mice.
S2, comparing the colon cancer treatment effect of the CD47 antibody and the CD47 antibody in combination with the IL-6 cytokine drug based on the transplantation tumor model, wherein the CD47 antibody in combination with the IL-6 cytokine drug comprises the CD47 antibody in combination with the IL-6 cytokine drug loaded on the nanometer material. In this example, mice were divided into eight different treatment groups, each treatment group consisting of 5 mice, each treatment group consisting of lgG + PBS, anti-CD47+ PBS, lgG + IL-6, anti-CD47+ IL-6, lgG + nano, anti-CD47+ nano, lgG + nano-IL-6, and anti-CD47+ nano-IL-6. After 7 days of injection, when the tumor volume grows to 50-100mm3200ug anti-CD47, 200ug lgG, 500ng or 1ug IL-6 intratumorally (or 150ug or 200ug BayK8644 intraperitoneally or Etoposide (VP-16) in a specific amount or other chemical drug capable of inducing IL-6), 500ng or 1ug nano-IL-6 intravenously (or 150ug or 200ug nano-BayK8644 or nano-Etoposide (VP-16) in a specific amount or nano-other chemical drug capable of inducing IL-6), and PBS (PBS) were injected in a corresponding combination according to the groups, once every three days and 4 times in total. And detecting the length (L), width (W) and height (H) of the mouse tumor every three days, calculating the tumor volume (L) W H/2, and finally analyzing the growth trend of the tumor volume and the tumor microenvironment. The IL-6 may be replaced with a specific amount of BayK8644 and the nano-IL-6 may beTo be replaced with a specific amount of nano-BayK 8644.
The result is similar to that of example 2, the anti-CD47+ nano-IL-6 group tumor size is less than that of the anti-CD47+ IL-6 group tumor size is less than that of other group tumors, animal experiments prove that the anti-CD47 and the IL-6 can effectively treat tumors, and the treatment effect is more obvious by loading the IL-6 on the nano material.
S3, comparing the effect of treating colon cancer with CD47 antibody, CD47 antibody in combination with IL-6 cytokine drug, CD47 antibody in combination with IL-6 cytokine drug and CSF-1R, CD47 antibody in combination with IL-6 cytokine drug and CD8 alpha based on the transplanted tumor model.
Take 1X 106A colon cancer cell line (MC38) was implanted subcutaneously into the right side of C57BL/6 mice. Mice were divided into four different treatment groups, 5 mice each: four groups are respectively injected with lgG + PBS, anti-CD47+ nano-IL-6, anti-CD47+ nano-IL-6+ CSF-1R antibody, anti-CD47+ nano-IL-6+ CD8+T cell deletion antibody. After 7 days, when the tumor volume grows to 50-100mm3Based on lgG, PBS, anti-CD47, nano-IL-6, CSF-1R anti body, CD8+And (3) carrying out corresponding matched injection on the corresponding groups by the T cell deletion antibody, wherein the injection is carried out once every three days and is totally carried out for four times. Mice were examined every three days for length (L), width (W) and height (H) of tumors, tumor volume was calculated as L W H/2, and tumor volume growth trends and tumor microenvironment were analyzed.
The results show that: anti-CD47+ nano-IL-6+ CSF-1 ranibody group and anti-CD47+ nano-IL-6+ CD8+The size of the tumors in the Tcellplementitiody group is larger than that in the anti-CD47+ nano-IL-6 group, which indicates that the nano-IL-6 promotes the anti-tumor effect of anti-CD47 by macrophages and CD8+T cell mediated.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the technical solutions of the present invention, and are not intended to limit the specific embodiments of the present invention. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention claims should be included in the protection scope of the present invention claims.
Claims (10)
- Use of a CD47 antibody in combination with an IL-6 cytokine drug in the preparation of an anti-tumor medicament, said IL-6 cytokine drug comprising an IL-6 cytokine and/or a pro-IL-6 cytokine drug.
- 2. The use according to claim 1, wherein the IL-6 cytokine-promoting medicament comprises BayK8644 agent and/or Etoposide (VP-16).
- 3. The use of claim 1, wherein the IL-6 cytokine drug is loaded on a nanomaterial targeted to the tumor or tumor microenvironment.
- 4. The use according to claim 1, characterized in that the antineoplastic drug is administered in combination with at least one anticancer treatment selected from the group consisting of immunotherapy, chemotherapy, radiotherapy, angiogenesis inhibitor therapy, biologic therapy, bone marrow transplantation, peripheral blood stem cell transplantation, thermotherapy, laser therapy, photodynamic therapy, cancer-targeted therapy.
- 5. The use of claim 1, wherein said anti-neoplastic agent is administered by enriching the tumor microenvironment with an IL-6 cytokine prior to administration of the CD47 antibody to the tumor.
- 6. Use according to any one of claims 1 to 4, wherein the tumour is colon cancer.
- 7. A kit comprising a CD47 antibody and an IL-6 cytokine drug, wherein the IL-6 cytokine drug comprises an IL-6 cytokine and/or a pro-IL-6 cytokine drug.
- 8. The kit of claim 6, further comprising a nanomaterial for loading an IL-6 cytokine drug to target a tumor or a tumor microenvironment.
- 9. A kit according to claim 7, wherein the IL-6 cytokine drug is loaded on the nanomaterial and administered prior to the CD47 antibody; alternatively, the IL-6 cytokine drug is loaded on a nanomaterial and administered concomitantly with the CD47 antibody.
- 10. A method for verifying that a CD47 antibody is used in combination with an IL-6 cytokine drug to effectively treat a tumor, comprising the steps of:s1, in-vitro phagocytosis detection, namely detecting the influence of the IL-6 cytokine drug on the phagocytosis of the CD47 antibody on the phagocytosis of the phagocyte by comparing the influence of the independent CD47 antibody and the CD47 antibody in combination with the IL-6 cytokine drug on the process of the phagocyte for phagocyting tumor cells;s2, animal tumor model-based tumor therapy testing, the effect of IL-6 cytokine drugs on the anti-tumor effect of CD47 was verified by comparing the effect of CD47 antibody alone and CD47 antibody in combination with IL-6 cytokine drugs on tumor development.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010636864.8A CN111905101B (en) | 2020-07-03 | 2020-07-03 | Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010636864.8A CN111905101B (en) | 2020-07-03 | 2020-07-03 | Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111905101A true CN111905101A (en) | 2020-11-10 |
| CN111905101B CN111905101B (en) | 2022-09-23 |
Family
ID=73227568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010636864.8A Active CN111905101B (en) | 2020-07-03 | 2020-07-03 | Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111905101B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024098939A1 (en) * | 2022-11-07 | 2024-05-16 | 北京伟德杰生物科技有限公司 | Bifunctional fusion protein and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016118754A1 (en) * | 2015-01-21 | 2016-07-28 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| CN110755387A (en) * | 2019-11-20 | 2020-02-07 | 深圳先进技术研究院 | Immune adjuvant-coated nanoparticle and application thereof |
| CN110831974A (en) * | 2017-06-21 | 2020-02-21 | 小利兰·斯坦福大学托管委员会 | Dosing parameters for CD47 targeted therapy against hematological malignancies |
-
2020
- 2020-07-03 CN CN202010636864.8A patent/CN111905101B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016118754A1 (en) * | 2015-01-21 | 2016-07-28 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| CN110831974A (en) * | 2017-06-21 | 2020-02-21 | 小利兰·斯坦福大学托管委员会 | Dosing parameters for CD47 targeted therapy against hematological malignancies |
| CN110755387A (en) * | 2019-11-20 | 2020-02-07 | 深圳先进技术研究院 | Immune adjuvant-coated nanoparticle and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| DIANE TSENG等: "Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response", 《PNAS》 * |
| XIN LIU等: "IL-6 expression promoted by Poly(I:C) in cervical cancer cells regulates cytokine expression and recruitment of macrophages.", 《J CELL MOL MED.》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024098939A1 (en) * | 2022-11-07 | 2024-05-16 | 北京伟德杰生物科技有限公司 | Bifunctional fusion protein and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111905101B (en) | 2022-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy | |
| Daniel et al. | The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies | |
| Zhang et al. | Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response | |
| CN112807434B (en) | Application of PERK inhibitor in preparation of synergist of liver cancer drug | |
| WO2021012886A1 (en) | Anti-neoplastic combined pharmaceutical composition and application thereof | |
| CN110755457B (en) | Method for overcoming tumor drug resistance | |
| WO2016172494A2 (en) | Combination of immunotherapy with local chemotherapy for the treatment of malignancies | |
| Zhao et al. | Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy | |
| WO2013078392A1 (en) | Methods and compositions involving induced senescent cells for cancer treatment | |
| Dai et al. | Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy | |
| CN111905101B (en) | Application of CD47 antibody and IL-6 cytokine drug in tumor treatment and method for verifying tumor treatment by using CD47 antibody and IL-6 cytokine drug | |
| US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
| JP2018513202A (en) | Combination therapy of anti-fugetactic agent and immunotherapeutic agent, and composition for cancer treatment | |
| JP2022130602A (en) | Modified natural killer cells having anti-fugetactic properties and uses thereof | |
| KR101858128B1 (en) | Pharmaceutical composition for treating cancer having radioresistant phenotype comprising SULF2 inhibitor | |
| CN111419832B (en) | Pharmaceutical composition and application thereof in preparation of tumor treatment drugs | |
| US20220378879A1 (en) | Application of peg interferon and protooncogene product targeting inhibitor in synergistic treatment of renal carcinoma | |
| CN115505601B (en) | Two-stage SynNotch logic regulation structure and application thereof | |
| CN114949000B (en) | Musk extract and application thereof in enhancing curative effect of CAR-T cells | |
| Datta et al. | Brain tumors: focus on glioblastoma | |
| CN111840541A (en) | Application of polyinosinic acid cytidylic acid and anti-CD 47 antibody in tumor treatment | |
| CN114081883B (en) | Application of cloquindol in preparation of antitumor drugs | |
| CN109913413B (en) | PD-1 antibody loaded T cell in-vitro culture method, cell preparation and application thereof | |
| JP2022028682A (en) | Modified t-cells having anti-fugetactic properties and uses thereof | |
| Nagai et al. | Late-Stage Ovarian Cancer With Systemic Multiple Metastases Marked Shrinkage Using a Combination of Wilms' Tumor Antigen 1 (WT1) Dendritic Cell Vaccine, Natural Killer (NK) Cell Therapy, and Nivolumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |